Drugs / YM543
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00454233 | Feb 2007 → Jun 2008 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YM543 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00454233 ↗ |
| Known as | ASP-543 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2397450 ↗ |
| Action | Inhibit | “Sodium/glucose cotransporter 2 inhibitor” CHEMBL2397450 ↗ |
| Modality | Small molecule | — CHEMBL2397450 ↗ |
| Route | Oral | “Oral” NCT00454233 ↗ |
| Target | SLC5A2 | “Sodium/glucose cotransporter 2 inhibitor” CHEMBL2397450 ↗ |